Clinical Trial

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and anlotinib in advanced breast cancer. Participants must have HER2-low and PD-L1 positive （CPS≥1）breast cancer that has been treated before. Participants' cancer: Cannot be removed by an operation Has spread to other parts of the body
Trial Details
NCT Number NCT06547476
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Breast Cancer
Enrollment 40 participants
Start Date 2024-09-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-09